{
    "clinical_study": {
        "@rank": "65664", 
        "brief_summary": {
            "textblock": "To determine the safety, toleration, and efficacy of fluconazole oral suspension in the\n      treatment of esophageal candidiasis in immunocompromised patients, including those with\n      AIDS."
        }, 
        "brief_title": "A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems", 
        "condition": [
            "Candidiasis, Esophageal", 
            "HIV Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Candidiasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive fluconazole oral suspension for a minimum of 3 weeks and maximum of 8\n      weeks. Patients are evaluated weekly, and treatment continues for 2 weeks after resolution\n      of symptoms. Endoscopic exams and possibly biopsies are performed at baseline and at the end\n      of treatment. Patients undergo follow-up at 2 weeks post-treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  AIDS or other immunocompromising condition.\n\n          -  Candidal esophagitis.\n\n          -  Life expectancy of at least 2 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Evidence of non-candidal systemic fungal infection.\n\n          -  Abnormalities that may preclude esophagoscopy or endoscopy.\n\n          -  Unable to tolerate fluconazole.\n\n          -  Unable to give informed consent.\n\n          -  Enrollment in other experimental trials of approved or non-approved drugs or systemic\n             compounds (unless approved by the Pfizer Clinical Monitor).\n\n          -  Other condition that would make patient unsuitable for enrollment.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Concomitant oral or topical antifungal agent.\n\n          -  Other experimental medications.\n\n        Patients with the following prior condition are excluded:\n\n        History of allergy to imidazoles or azoles.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Any oral or topical antifungal therapy within the past 3 days. Active use of illicit\n             or illegal drugs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "13 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002339", 
            "org_study_id": "120", 
            "secondary_id": "R-0220"
        }, 
        "intervention": {
            "intervention_name": "Fluconazole", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fluconazole"
        }, 
        "keyword": [
            "Esophagitis", 
            "Fluconazole", 
            "Acquired Immunodeficiency Syndrome", 
            "Candidiasis", 
            "Immunocompromised Host"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Los Angeles County - USC Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Houston Veterans Administration Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "An Open Multicenter Trial of Fluconazole Oral Suspension in the Treatment of Esophageal Candidiasis in Immunocompromised Patients", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "reference": {
            "PMID": "7957784", 
            "citation": "Agresti MG, de Bernardis F, Mondello F, Bellocco R, Carosi GP, Caputo RM, Milazzo F, Chiodo F, Giannini V, Minoli L, et al. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study. Eur J Epidemiol. 1994 Feb;10(1):17-22."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002339"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "Houston Veterans Administration Med Ctr": "29.76 -95.369", 
        "Los Angeles County - USC Med Ctr": "34.052 -118.244"
    }
}